Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
2.1400
+0.5100 (31.29%)
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of cancer
The company's expertise lies in its ability to identify and target specific molecular pathways that drive cancer growth and progression. Zentalis is dedicated to advancing a pipeline of small molecules designed to address high unmet medical needs in oncology. Through a combination of scientific rigor and a commitment to patient care, the company aims to deliver effective treatment options that can improve outcomes for individuals battling cancer.
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQZNTL) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ZNTL.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQZNTL) for violations of the securities laws.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.
Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology.
